Clinical trials: Withdrawal
Psoriasis
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
- Trial name
- AMAGINE-1 (NCT01708590)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 78 sites in United States, Canada and 4 more
- Volunteers
- 661 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid Withdrawal, Opioid Use Disorder
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
The primary objective of this trial is to measure changes in physiologic signals to quantify the status of the autonomic nervous system during opioid withdrawal and cravings.
- Trial name
- NCT06487533
- Testing
- EmbracePlus Smartwatch, Corti Sensor
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Gastroesophageal Reflux, Heartburn
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
- Trial name
- NCT00236392
- Testing
- rabeprazole
- Volunteers
- 422 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Pro-opiomelanocortin (POMC) Deficiency Obesity
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type…
- Trial name
- NCT02896192
- Testing
- Setmelanotide
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Muscular Dystrophy, Oculopharyngeal (OPMD)
Continuation Protocol to Protocol BBCO-001
This will be a multi-center, randomized withdrawal, open-label, non-treatment concurrent control, parallel group study. Patients completing protocol BBCO-001 will be offered the opportunity to enter into this 12-month randomized…
- Trial name
- HOPEMD (NCT02328482)
- Testing
- Tehalose 30gr
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- Bioblast Pharma Ltd.
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC
Sexual Dysfunction, Ejaculation
A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
The primary purpose of the study is to assess the possible withdrawal effects after abruptly stopping daily therapy with dapoxetine compared with continuing daily therapy in men with premature ejaculation (PE).
- Trial name
- NCT00210613
- Testing
- Dapoxetine
- Volunteers
- 199 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Vitiligo
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who…
- Trial name
- NCT04530344
- Testing
- ruxolitinib, Vehicle
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 458 people
- Sponsor
- Incyte Corporation
Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
- Trial name
- NCT07686263
- Testing
- Xanomeline/Trospium Chloride
- Where
- 54 sites in United States, Argentina and 5 more
- Volunteers
- 472 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Muckle Wells Syndrome
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
This study is designed to provide efficacy and safety data for ACZ885 (a fully human anti-interleukin-1beta (anti-IL-1beta) monoclonal antibody) administered as an injection subcutaneously (s.c.) in patients with Muckle-Wells…
- Trial name
- REMITTER (NCT00465985)
- Testing
- ACZ885
- Where
- 12 sites in United States, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Novartis
Major Depressive Disorder
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design.
- Trial name
- NCT00887224
- Testing
- Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg
- Where
- 90 sites in United States, Canada and 12 more
- Volunteers
- 874 people
- Sponsor
- Pfizer
Asthma
AZD1419 Ph2a Study
Ph2a study planned to be run at approximately 16-18 sites in 4 EU countries (Denmark, Hungary, Poland and Sweden) enrolling approximately 170 patients to ensure 70 randomized patients with eosinophilic, moderate to severe asthma.
- Trial name
- INCONTRO (NCT02898662)
- Testing
- AZD1419
- Where
- 15 sites in Denmark, Hungary and 2 more
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the…
- Trial name
- NCT05513001
- Testing
- LOU064 (blinded), LOU064 (open label)
- Where
- 208 sites in United States, Argentina and 28 more
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Use Disorder, Opioid Withdrawal
Suboxone Dispenser for OUD
The goal of this study is to evaluate the usability and acceptability of the Addinex system with patients receiving Suboxone in OUD treatment.
- Trial name
- NCT05790551
- Testing
- Addinex
- Where
- United States
- Sponsor
- Addinex Technologies, Inc.
Chronic Pain, Low Back Pain
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
The primary objective of the study is to determine the analgesic efficacy and safety of ALO-02 extended-release capsules, when compared to placebo, in subjects with moderate to severe chronic low back pain.
- Conditions
- Chronic Pain, Low Back Pain, Analgesia
- Trial name
- NCT01571362
- Testing
- ALO-02
- Where
- 52 sites in United States
- Volunteers
- 410 people
- Sponsor
- Pfizer
Major Depressive Disorder
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep, overall quality of life, and effect, if any, on…
- Trial name
- AMETHYST (NCT00278941)
- Testing
- Quetiapine Fumarate Sustained Release
- Where
- 168 sites in United States, Bulgaria and 6 more
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Schizophrenia
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using olanzapine 15 mg once daily as active control.
- Trial name
- GUEST (NCT00988728)
- Testing
- SCH 900435 (Org 25935), Olanzapine
- Sponsor
- Merck Sharp & Dohme LLC
Spondylitis, Ankylosing
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
- Trial name
- RE-EMBARK (NCT02509026)
- Testing
- Etanercept
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 210 people
- Sponsor
- Pfizer
Opioid Dependence
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- NCT00447564
- Testing
- Probuphine
- Where
- 18 sites in United States
- Volunteers
- 163 people
- Sponsor
- Titan Pharmaceuticals
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals